Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Everest Reports ADC Meets Endpoint for Triple-Negative Breast Cancer

publication date: Nov 12, 2021

Everest Medicines reported its novel TROP-2 antibody-drug conjugate met its primary endpoint in a China Phase II trial in metastatic triple-negative breast cancer (TNBC) patients. In 2019, Everest in-licensed the candidate in an $835 million agreement. Sacituzumab govitecan, which is marketed as Trodelvy® in the US by Gilead, met its primary endpoint of overall response rate as a third line treatment for TNBC. Earlier this year, Everest began a China Phase III trial of the ADC in patients with metastatic urothelial cancer. More details....

Stock Symbols: (HK 1952) (NSDQ: GILD)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here